Back to Search
Start Over
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam
- Source :
- Antimicrob Agents Chemother
- Publication Year :
- 2021
- Publisher :
- American Society for Microbiology, 2021.
-
Abstract
- Ceftolozane-tazobactam (C/T) is a new fifth-generation cephalosporin/beta-lactamase inhibitor combination approved by the Food and Drug Administration and the European Medicines Agency for treatment of complicated intraabdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia in adult patients. This review will briefly describe the pharmacology of C/T and focus on the emerging clinical trial and real-world data supporting its current utilization. Additionally, our synthesis of these data over time has set our current usage of C/T at Barnes-Jewish Hospital (BJH). C/T is primarily employed as directed monotherapy at BJH when Pseudomonas aeruginosa isolates are identified with resistance to other beta-lactams. C/T can also be used empirically in specific clinical situations at BJH prior to microbiological detection of an antibiotic-resistant P. aeruginosa isolate. These situations include critically ill patients in the intensive care unit (ICU) setting, where there is a high likelihood of infection with multidrug-resistant (MDR) P. aeruginosa; patients failing therapy with a carbapenem; specific patient populations known to be at high risk for infection with MDR P. aeruginosa (e.g., lung transplant and cystic fibrosis patients); and patients know to have previous infection or colonization with MDR P. aeruginosa.
- Subjects :
- Adult
Tazobactam
medicine.medical_specialty
Carbapenem
Microbial Sensitivity Tests
Drug resistance
medicine.disease_cause
law.invention
03 medical and health sciences
0302 clinical medicine
Antibiotic resistance
law
Drug Resistance, Multiple, Bacterial
Internal medicine
medicine
Humans
Pseudomonas Infections
Pharmacology (medical)
030212 general & internal medicine
Pharmacology
0303 health sciences
030306 microbiology
Pseudomonas aeruginosa
business.industry
medicine.disease
Antimicrobial
Intensive care unit
Anti-Bacterial Agents
Cephalosporins
Pneumonia
Infectious Diseases
Perspective
business
medicine.drug
Subjects
Details
- ISSN :
- 10986596 and 00664804
- Volume :
- 65
- Database :
- OpenAIRE
- Journal :
- Antimicrobial Agents and Chemotherapy
- Accession number :
- edsair.doi.dedup.....52fb1908c5ae52d73e3a1fa02f6b5023